Test Price
2,800 AED✅ Home Collection Available
SLC35A3 Gene Arthrogryposis, Intellectual Disability, and Seizures Genetic Test in UAE
Executive Summary & Core Metrics
This advanced Next-Generation Sequencing (NGS) test analyzes the entire coding region of the SLC35A3 gene to identify pathogenic variants causative of arthrogryposis, intellectual disability, and seizures. It delivers a definitive molecular diagnosis with a turnaround time of 3–4 weeks and exceeds 99.9% analytical sensitivity.
Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM daily).
Clinical Guidance
Post-test telephonic genetic counseling included with every report.
Insurance
Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Our targeted single-gene NGS test provides ultra-deep coverage of the SLC35A3 gene using Illumina NovaSeq X Plus technology, delivering results faster and more cost-effectively than whole exome sequencing (WES).
| Feature | Our Test: Single-Gene NGS | Whole Exome Sequencing (WES) |
|---|---|---|
| Precision | Ultra-deep coverage of SLC35A3 (>500x) | Generalized, typically 100–150x coverage |
| Method | Illumina NovaSeq X Plus NGS | Whole Exome Capture + NGS |
| Turnaround Time | 3–4 Weeks | 8–12 Weeks |
| Cost (AED) | 2,800 | >5,000 |
Physician Insight & Safety Protocols
As a Consultant Medical Genetics at DNA Labs UAE, I counsel patients that the identification of a pathogenic SLC35A3 variant provides a definitive diagnosis. However, this result must be integrated with clinical findings and a multidisciplinary approach for optimal management. Genetic counseling is essential both before and after testing, and no therapeutic decision should be made solely on this report.
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory
Medication Warning: Do not discontinue or adjust any prescribed antiepileptic or muscle relaxant medications without consulting your treating physician. This test result is for diagnostic confirmation only and does not replace ongoing medical management.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: This test is not validated for somatic mosaicism detection, minimal residual disease monitoring, or prenatal diagnosis (separate arrangement required). Not recommended for asymptomatic minors without informed guardian consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags: If you experience new-onset generalized tonic-clonic seizures, severe difficulty breathing due to chest wall contractures, or acute joint dislocation, seek immediate emergency medical care.
Patient FAQ & Clinical Guidance
1. What exactly does the SLC35A3 gene test diagnose?
This test definitively diagnoses SLC35A3-related congenital disorder of glycosylation causing arthrogryposis, intellectual disability, and seizures. It detects single nucleotide variants, small insertions/deletions, and copy number changes within the gene, providing a molecular confirmation that guides clinical management, recurrence risk assessment, and family planning.
2. How is the sample collected for this genetic test?
A simple blood draw (whole blood in EDTA tube) or a single drop of blood on an FTA card is all that is required. Our DHA-licensed phlebotomists offer a VIP mobile home collection service throughout Dubai, Abu Dhabi, and Sharjah, ensuring cold-chain transport to our ISO-certified laboratory for processing.
3. How accurate are the results and can they be used for treatment?
Our NGS achieves analytical sensitivity and specificity exceeding 99.9% for detecting SLC35A3 variants. A positive result confirms the genetic diagnosis, enabling targeted interventions and specialist referrals, but treatment must be guided by a multidisciplinary medical team based on the full clinical context.
UAE Regulatory & Data Privacy Adherence
- ✓ Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- ✓ All clinical testing safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
- ✓ ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) for laboratory and logistics operations.
- ✓ Facility licensed by DHA (License No: 1143) and operates under DNA Labs UAE corporate brand.
Clinical & Logistical Metadata
| Test Name | SLC35A3 Gene Arthrogryposis, Intellectual Disability, and Seizures Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina NovaSeq X Plus |
| ICD-10-CM Code | E77.8 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians